Real world effectiveness and safety of oral Janus kinase inhibitor in vitiligo: a retrospective study.

Authors

Xiaoyi Shi, Yukun Yuan, Rongsi Sun, Mengyi Zhu, Juan Du, Fang Wang, Xiaolan Ding

Published in

Journal of the American Academy of Dermatology. Sep 19, 2025. Epub Sep 19, 2025.

Abstract

Increasing numbers of studies have demonstrated that oral Janus kinase inhibitors (JAKi) are effective in the treatment of vitiligo. However, large-scale data on their effectiveness and safety remain limited.
We aimed to assess the effectiveness and safety of oral JAKi in vitiligo treatment and explore potential predictive factors associated with response to JAKi under real-world conditions.
A retrospective study was conducted in vitiligo patients who had received oral JAKi for at least 3 months. The overall response rate was the total percentage of patients who achieved > 25% repigmentation. Multivariable logistic regression analysis identified predictors for response and oral JAKi.
A total of 96 patients were included, 86 (89.6%) of whom achieved different degrees of repigmentation. The overall response rate was 55.2%, and the rate of marked repigmentation (≥ 76%) was 9.4%. Age, history of phototherapy, and oral JAKi administration for more than 6 months were independent predictors of response to JAKi. No severe adverse events were observed.
Single-center study with limited patients.
Oral JAKi were effective and safe for patients with vitiligo. Patients taking oral JAKi for more than 6 months had better outcomes than those who received JAKi for a shorter period.

PMID:
40976534
Bibliographic data and abstract were imported from PubMed on 22 Sep 2025.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.